The Cancer Letter

Inside information on cancer research and drug development

Iowa’s Mark Burkard sees a role for data science in bringing clinical trials to rural clinics
The state has the second highest (and rising) cancer rates in the U.S.

In Brief

UChicago receives $75M from AbbVie Foundation for construction of the cancer care and research pavilion

Longevity Consortium receives $45M grant

Ruling changes NY law, restores oncologists ability to provide supportive therapies in-office

UF Health Cancer Center rolls out mobile cancer screening vehicle

UNM CCC receives three-year reaccreditation from the Commission on Cancer

University of Hawai‘i Cancer Center receives NCI designation with “outstanding” score

Drugs & Targets

FDA approves Scemblix for newly diagnosed CML patients

Pangea Biomed, OHSU Knight Cancer Institute collaborate to improve cancer therapy precision

FDA approves Vyloy+chemo for gastric or GEJ junction adenocarcinoma with CLDN18.2-positive tumors

FDA accepts NDA, grants priority review for Pixclara glioma imaging agent

EC approves Keytruda combinations for endometrial carcinoma indication, FIGO 2014 stage III-IVA locally advanced cervical cancer

EMA CHMP grants positive opinion of Korjuny for malignant ascites

In The Clinic

GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation

Trials & Tribulations

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account